Evgen Revenue and Competitors
Estimated Revenue & Valuation
- Evgen's estimated annual revenue is currently $1.6M per year.
- Evgen's estimated revenue per employee is $201,000
Employee Data
- Evgen has 8 Employees.
- Evgen grew their employee count by -27% last year.
Evgen's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Business Officer | Reveal Email/Phone |
3 | Development Project Leader | Reveal Email/Phone |
Evgen Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Evgen?
Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.
keywords:N/AN/A
Total Funding
8
Number of Employees
$1.6M
Revenue (est)
-27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Evgen News
Evgen Kramarenko, director of the Ukrainian state agency managing the exclusion zone around the Chernobyl plant, sent the photos to VOA on...
Evgen Revun has lived half his life on the edge of a conflict zone. The Russian annexation of Crimea in 2014 and the subsequent proclamation of...
Evgen Pharma PLC's (LON:EVG) Dr Huw Jones joins Proactive London to go through their portfolio with progress for is lead asset on two fronts in...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.2M | 37 | 0% | N/A |
#2 | $4.6M | 40 | N/A | N/A |
#3 | $6.8M | 52 | N/A | N/A |
#4 | $11.8M | 65 | -4% | N/A |
#5 | $12.3M | 65 | 8% | N/A |